• Dosing of first patient initiates Phase 1 clinical evaluation of BMS-986506 for the treatment of advanced clear cell renal cell carcinoma, the most common form of kidney cancer
  • Transformative moment in strategic protein degradation collaboration with Bristol Myers Squibb (BMS) aiming to establish new treatment paradigm in advanced clear cell renal cell carcinoma
  • Study start highlights transition into the clinic for Evotec-BMS oncology platform and reflects robust pipeline of 'molecular glues' being advanced as treatment options for different cancer types
  • Validates Evotec's high-performance multi-omics screening and AI-supported data analytics and drug design capabilities